Advertisement
Journal Home
Search for

Volume 122, Issue 11, Pages 1016-1022.e1 (November 2009)


View previous. 12 of 31 View next.

Bayesian Meta-analysis of Hormone Therapy and Mortality in Younger Postmenopausal Women

Shelley R. Salpeter, MDabCorresponding Author Informationemail address, Ji Cheng, MScc, Lehana Thabane, PhDc, Nicholas S. Buckleyd, Edwin E. Salpeter, PhD (Posthumous)e

Abstract 

Background

There is uncertainty over the risks and benefits of hormone therapy. We performed a Bayesian meta-analysis to evaluate the effect of hormone therapy on total mortality in younger postmenopausal women. This analysis synthesizes evidence from different sources, taking into account varying views on the issue.

Methods

A comprehensive search from 1966 through January 2008 identified randomized controlled trials of at least 6 month's duration that evaluated hormone therapy in women with mean age <60 years and reported at least one death, and prospective observational cohort studies that evaluated the relative risk of mortality associated with hormone therapy after adjustment for confounding variables.

Results

The results were synthesized using a hierarchical random-effects Bayesian meta-analysis. The pooled results from 19 randomized trials, with 16,000 women (mean age 55 years) followed for 83,000 patient-years, showed a mortality relative risk of 0.73 (95% credible interval 0.52-0.96). When data from 8 observational studies were added to the analysis, the resultant relative risk was 0.72 (credible interval 0.62-0.82). The posterior probability that hormone therapy reduces total mortality in younger women is almost 1.

Conclusions

The synthesis of data using Bayesian meta-analysis indicates a reduction in mortality in younger postmenopausal women taking hormone therapy compared with no treatment. This finding should be interpreted taking into account the potential benefits and harms of hormone therapy.

a Santa Clara Valley Medical Center, San Jose, Calif

b Stanford University, Palo Alto, Calif

c McMaster University, Hamilton, Ontario, Canada

d California Institute of Technology, Pasadena

e Cornell University, Ithaca, NY

Corresponding Author InformationRequests for reprints should be addressed to Shelley R. Salpeter, MD, Santa Clara Valley Medical Center, 751 S. Bascom Ave, San Jose, CA 95128

 Funding: No research funding.

 Conflict of Interest: Dr. Salpeter has consulted in the past with law firms representing Wyeth Pharmaceuticals on issues involving hormone therapy, and was paid on an hourly basis. Dr. Thabane consults with GlaxoSmithKline on statistical and methodological issues. The other authors report no potential conflicts of interest.

 Authorship: All authors had access to the data and had a role in writing the manuscript. Edwin Salpeter died after the preparation and approval of the manuscript.

PII: S0002-9343(09)00666-4

doi:10.1016/j.amjmed.2009.05.021


View previous. 12 of 31 View next.

Advertisement